Clinical trials
Severe Alopecia Areata clinical trials
Below are recruiting severe alopecia areata clinical trials, each written for real people, not researchers. We’re tracking 24 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07749716RecruitingPhase 2
Oral tablet for severe hair loss
This study tests an experimental oral tablet for severe alopecia areata, a condition that causes patches of hair to fall out. The goal is to see if it can help regrow hair safely. You may be able to join if you have this type of hair loss and meet the health requirements.
Beijing, Beijing MunicipalityAges 18–65 - NCT07772492RecruitingPhase 3
Study of upadacitinib for teens with severe hair loss
This study tests if upadacitinib can help young people with severe alopecia areata (a condition causing patchy hair loss) regrow their hair. It may be an option if hair loss has been present for less than 8 years and there has been no recent improvement.
Miami, FloridaAges 6–17 - NCT06873945RecruitingPhase 3
Study of two doses of ritlecitinib for alopecia areata
This study tests two different doses of a pill called ritlecitinib to see if it can help regrow hair in people with significant hair loss from alopecia areata. It is for people aged 12 and older who have lost at least half of their scalp hair.
Birmingham, AlabamaAges 12 years+ - NCT06012240RecruitingPhase 3
Testing Upadacitinib for Severe Alopecia Areata
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
Birmingham, AlabamaAges 12–63 - NCT07733063Recruiting
Blood markers for ferroptosis in Alopecia Areata
This study looks at certain blood markers (GPX4 and MDA) related to a process called ferroptosis in people with Alopecia Areata. The goal is to better understand this condition and possibly find new treatment targets.
Istanbul, Cerrahpasa MahallesiAges 18–65 - NCT05723198RecruitingPhase 3
Baricitinib for severe childhood hair loss from alopecia areata
This trial tests whether baricitinib can improve severe alopecia areata (patchy, autoimmune hair loss) in children and teens. It’s meant for people who have had long-lasting, severe hair loss and have tried other treatments without enough benefit.
Birmingham, AlabamaAges 6–17 - NCT05866562RecruitingPhase 2
Dupilumab for hair regrowth in kids with alopecia areata
This trial studies dupilumab (an injection medicine) to help grow hair in children and teens with alopecia areata, an autoimmune hair-loss condition. It aims to see whether the treatment improves hair regrowth compared with usual care over the study period.
Irvine, CaliforniaAges 6–17 - NCT06104839RecruitingPhase 2
Oral NXC-736 for moderate to severe alopecia areata
This trial tests an oral medication called NXC-736 for people with moderate to severe alopecia areata. It aims to see if the drug is safe and can help regrow hair.
SeoulAges 19–65 - NCT06747611RecruitingPhase 2
Gut bacteria transplant for alopecia areata
This study tests whether transplanting healthy gut bacteria can help people with moderate to severe alopecia areata regrow hair. You will take antibiotics to prepare your gut, then receive the transplant through a colonoscopy or capsules.
Minneapolis, MinnesotaAges 18–75 - NCT06826196RecruitingPhase 1/Phase 2
Testing a new shot for patchy hair loss (alopecia areata)
This study tests a new medicine called ALD-102, given as a small shot in the scalp, to see if it helps hair grow back in people with alopecia areata. It is an early-stage trial looking at safety, how the body handles the drug, and whether it works.
Thousand Oaks, CaliforniaAges 18–55 - NCT07029828RecruitingPhase 3
Long-term study of ritlecitinib for severe alopecia areata in children
This study tests a medicine called ritlecitinib for children with severe alopecia areata (a condition causing hair loss). It is for kids who have already completed a previous study of this medicine to see how well it works and how safe it is over a longer period.
Encinitas, CaliforniaAges 6–14 - NCT07133308RecruitingPhase 3
Study of deuruxolitinib for teens with severe alopecia areata
This study tests an investigational oral medication (deuruxolitinib) for adolescents with severe alopecia areata (hair loss). It aims to see if it can help hair regrow safely.
Birmingham, AlabamaAges 12–17 - NCT07152119Recruiting
Study of Litfulo for severe alopecia areata in routine care
This study looks at how well Litfulo capsules work for people with severe alopecia areata in everyday medical practice. It is for adults and teens aged 12 or older who are starting Litfulo as part of their normal care.
SeoulAges 12 years+ - NCT07205159RecruitingPhase 1
A study of FB102 for severe alopecia areata
This trial tests a new drug called FB102 for people with severe to very severe alopecia areata, a condition that causes at least half of scalp hair to be lost. It aims to see if the drug is safe and can help hair grow back.
Saint Leonards, New South Wales (nsw)Ages 18–75 - NCT07617597RecruitingPhase 3
Testing deuruxolitinib for severe hair loss in Japanese adults
This study tests whether a new drug called deuruxolitinib can help regrow hair in people with alopecia areata (an autoimmune condition causing patchy hair loss). The drug works by blocking certain immune signals that attack hair follicles.
AsahikawaAges 18–65 - NCT07311564RecruitingPhase 2
Study of LAD603 for adults with severe alopecia areata
This trial tests a new medication called LAD603 for people with severe to very severe alopecia areata, a condition causing significant hair loss. It aims to see if the drug can help regrow hair.
Omaha, NebraskaAges 18–65 - NCT07381556RecruitingPhase 4
Comparing cyclosporine and methotrexate for kids with alopecia areata
This study compares two medicines, cyclosporine and methotrexate, to see which works better for children with alopecia areata (a condition causing hair loss). It aims to help doctors choose the best treatment for each child.
RotterdamAges 2–17 - NCT07533006RecruitingPhase 2
Testing LY4005130 for severe hair loss (alopecia areata)
This study tests whether a new drug called LY4005130 can help regrow hair in adults with severe alopecia areata (an autoimmune condition causing patchy or widespread hair loss). The trial is looking for people who have lost a significant amount of hair and haven't seen it grow back on its own for at least 6 months.
Fremont, CaliforniaAges 18–50 - NCT07554222RecruitingPhase 1
Safety study of IBI3013 for vitiligo and hair loss
This is an early-stage safety study of a new drug called IBI3013. The trial tests how safe the drug is and how your body processes it. It enrolls healthy volunteers first, then people with vitiligo (loss of skin color) or severe alopecia areata (patchy hair loss).
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06562270Recruiting
Teens with severe alopecia areata: treatment safety study
This study tracks the safety and effectiveness of alopecia areata treatments in teenagers aged 12-17. It helps doctors understand which treatments work best and are safest for young people with severe hair loss.
Waltham, MassachusettsAges 12–17 - NCT05398809RecruitingPhase 2
Ruxolitinib for hair regrowth in APECED-related alopecia areata
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
Bethesda, MarylandAges 12–75 - NCT07136467Recruiting
Understanding daily life with vitiligo, alopecia areata, or hidradenitis suppurativa
This study looks at how certain skin conditions affect daily life in teens and adults. Researchers want to understand the challenges people face with vitiligo, alopecia areata, or hidradenitis suppurativa by having participants fill out simple questionnaires.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 12 years+ - NCT07242638RecruitingPhase 2
Abrocitinib for skin and hair loss in Down syndrome
This study tests if the pill abrocitinib can help people with Down syndrome who have atopic dermatitis (eczema) or alopecia areata (patchy hair loss). The goal is to see if it improves their skin or hair with manageable side effects.
New York, New YorkAges 12 years+ - NCT05551793RecruitingPhase 2
Dupilumab for patchy hair loss with scalp inflammation
This Phase 2 trial tests dupilumab (an injection medicine) to regrow hair in people with alopecia areata, a condition where the immune system attacks hair follicles. It may help by reducing the immune-related inflammation linked to hair loss.
Irvine, CaliforniaAges 18 years+
Hear when a new Severe Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for severe alopecia areata?
- Yes. Clin2 currently lists 24 recruiting severe alopecia areata studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a severe alopecia areata trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a severe alopecia areata trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.